DZ Bank reaffirmed their buy rating on shares of Merck KGaA (FRA:MRK) in a research note released on Monday morning.

A number of other equities analysts also recently weighed in on MRK. JPMorgan Chase & Co. set a €95.00 ($117.28) price target on Merck KGaA and gave the stock a neutral rating in a research report on Monday. Kepler Capital Markets set a €115.00 ($141.98) price target on Merck KGaA and gave the stock a buy rating in a research report on Monday, November 6th. Independent Research set a €103.00 ($127.16) price target on Merck KGaA and gave the stock a neutral rating in a research report on Thursday, November 9th. Berenberg Bank set a €116.00 ($143.21) price target on Merck KGaA and gave the stock a buy rating in a research report on Thursday, November 9th. Finally, Commerzbank set a €103.00 ($127.16) price target on Merck KGaA and gave the stock a neutral rating in a research report on Thursday, October 26th. Eleven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Merck KGaA currently has an average rating of Buy and an average price target of €107.57 ($132.80).

Merck KGaA (FRA:MRK) opened at €83.16 ($102.67) on Monday. The firm has a market capitalization of $10,770.00 and a P/E ratio of 19.48. Merck KGaA has a 12-month low of €80.50 ($99.38) and a 12-month high of €115.00 ($141.98).

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://theolympiareport.com/2018/02/15/dz-bank-reiterates-buy-rating-for-merck-kgaa-mrk.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.